Study Designs and Crafting Endpoints for Gene Therapy Development Programs in Rare Disease: A Narrative Review

Area of Science:

• * Gene therapy development and regulatory science.
• * Clinical trial design for rare diseases.
• * Rare genetic disease therapeutics.

Background:

• * Limited treatment options exist for rare genetic diseases, often failing to address underlying mechanisms.
• * Gene therapies represent a promising therapeutic strategy for these conditions.
• * Significant challenges impede gene therapy development, including trial design and regulatory frameworks.

Purpose of the Study:

• * To provide insights from 12 successful gene therapy clinical development programs (2016-2023).
• * To identify and analyze strategies for overcoming challenges in gene therapy trials.
• * To inform the design of future gene therapy studies for rare genetic diseases.

Main Methods:

• * Systematic review and analysis of 12 clinical development programs for gene therapies.
• * Examination of strategies employed in trials for rare genetic diseases.
• * Documentation of insights from programs leading to recent gene therapy approvals.

Main Results:

• * Successful gene therapy approvals highlight effective strategies for trial navigation.
• * Key strategies include early regulatory engagement, patient involvement, and robust endpoint selection.
• * Real-world data aids in understanding long-term efficacy, durability, and safety.

Conclusions:

• * Data-driven solutions can be derived from analyzing past gene therapy programs.
• * These solutions can improve trial efficiency and accelerate the development of rare disease therapies.
• * Evidence-based approaches may challenge preconceptions but strengthen the foundation for future studies.